Date: 2011-12-01
Type of information: Development agreement
Compound: ficlatuzumab
Company: Boehringer Ingelheim (Germany) AVEO Pharmaceuticals (USA)
Therapeutic area: Cancer - Oncology
Type agreement: development
manufacturing
production
Action mechanism:
Disease: non small cell lung cancer
Details: AVEO Pharmaceuticals and Boehringer Ingelheim have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s novel HGF inhibitory antibody that is currently in phase II clinical development in patients with non-small cell lung cancer (NSCLC). Boehringer Ingelheim will produce ficlatuzumab for clinical trials at its biopharmaceutical site in Fremont, USA. AVEO retains all rights to the development and commercialization of ficlatuzumab.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
